Le Lézard
Classified in: Health
Subject: PDT

Armas Pharmaceuticals Announces the Reintroduction of Lidocaine Jelly 2% 30mL to the U.S. Market


FREEHOLD, N.J., March 27, 2025 /PRNewswire/ -- Armas Pharmaceuticals, a leading provider of high-quality pharmaceutical products, is pleased to announce the reintroduction of Lidocaine Jelly 2% 30mL to the U.S. market. This key product has been unavailable for more than two years, and its return underscores Armas' commitment to providing critical medications with a focus on consistent supply and sustainability.

Lidocaine Jelly 2% is a topical anesthetic used in various medical applications, including urological and endoscopic procedures, to provide localized pain relief.  Its reintroduction is expected to address a significant gap in the market and meet the needs of healthcare providers nationwide.

"Our mission at Armas Pharmaceuticals is to ensure that essential medications remain consistently available to the healthcare community," said Joe Niemi, President & CEO of Armas Pharmaceuticals. "The return of Lidocaine Jelly 2% 30mL represents our ongoing commitment to supply chain sustainability and our ability to respond to critical product needs in the market. We will continue to expand our portfolio with a focus on reliability, quality, and patient care."

Armas Pharmaceuticals continues to strengthen its presence in the pharmaceutical industry by offering a robust and growing portfolio of high-quality products. With a steadfast commitment to innovation and supply chain security, the company remains dedicated to addressing critical healthcare needs in the U.S. market.
For more information on Lidocaine Jelly 2% 30mL and other Armas Pharmaceuticals products, please visit www.armaspharma.com.

About Armas Pharmaceuticals
Armas Pharmaceuticals is a leading specialty pharmaceutical company committed to providing high-quality, accessible, and sustainable medications to the U.S. market. With a diverse portfolio spanning multiple therapeutic areas, Armas focuses on ensuring the consistent availability of essential medicines for healthcare providers and patients.

Contact:
Jenifer Arabia 
Vice President, Marketing and Operations
Armas Pharmaceuticals
Email: [email protected]  
Phone: 732-637-1971

SOURCE Armas Pharmaceuticals


These press releases may also interest you

at 11:00
Medtronic Evoluttm TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients
Medtronic plc , a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evoluttm transcatheter aortic valve replacement (TAVR) system delivers...

at 10:00
SCORE analysis of semaglutide 2.4 mg demonstrated reduction in cardiovascular events in a real-world setting
Today, Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults with overweight or obesity and established...

at 09:43
Fosun International Announces 2024 Annual Results: Total Revenue Reaches RMB192.14 Billion, Industrial Operation Profit Amounts to RMB4.9 Billion, Overall Operational Fundamentals Remain Stable
Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today announced its annual results for the year ended 31 December 2024 (the "Reporting Period"). In 2024, Fosun...

at 07:10
Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2...

29 mar 2025
Oral semaglutide 14 mg demonstrated superior reduction in risk of cardiovascular events in late-breaking SOUL trial presented at the American College of Cardiology
Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial investigating the effects of Rybelsus® (semaglutide) tablets 14 mg on reducing the risk of major adverse cardiovascular events (MACE) in adults with type...

29 mar 2025
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with...

More news about Health...


News published on and distributed by: